OmniAb, Inc. (NASDAQ:OABI) Insider Charles S. Berkman Sells 8,215 Shares

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 8,215 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total value of $30,231.20. Following the completion of the transaction, the insider now owns 364,131 shares of the company’s stock, valued at approximately $1,340,002.08. The trade was a 2.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

OmniAb Stock Down 5.9 %

Shares of NASDAQ:OABI opened at $3.65 on Friday. The company has a 50-day moving average price of $3.48 and a 200 day moving average price of $3.90. OmniAb, Inc. has a 52 week low of $3.10 and a 52 week high of $6.55. The company has a market cap of $515.45 million, a P/E ratio of -5.89 and a beta of -0.12.

Analyst Ratings Changes

Several analysts have commented on the stock. Benchmark restated a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th.

Institutional Investors Weigh In On OmniAb

Large investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC acquired a new stake in shares of OmniAb during the 4th quarter worth about $38,000. Choreo LLC purchased a new position in shares of OmniAb in the 4th quarter worth $41,000. Rangeley Capital LLC acquired a new position in shares of OmniAb in the 4th quarter valued at about $41,000. CWC Advisors LLC. acquired a new stake in shares of OmniAb in the third quarter worth $54,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in OmniAb in the 4th quarter valued at $49,000. 72.08% of the stock is owned by institutional investors and hedge funds.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.